Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
Thejus Jayakrishnan(Cleveland Clinic), Sikander Ailawadhi(Jacksonville College), Asher Chanan‐Khan(WinnMed), Taimur Sher(Mayo Clinic in Florida), Aneel Paulus(WinnMed), Rami Manochakian(Mayo Clinic in Florida), Kianna M. Nguyen(Mayo Clinic in Arizona), Mizba Baksh(Mayo Clinic in Florida), Ricardo Parrondo(Jacksonville College), Sonikpreet Aulakh(West Virginia University), Meghna Ailawadhi(Mayo Clinic in Florida), Vivek Roy(Jacksonville College), Ayesha Samreen(Mayo Clinic in Florida)
Cited by 20
Related Papers
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
|Blood|2011|450
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
|Blood|2017|271
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis
|Annals of Surgical Oncology|2014|252